Single nucleotide polymorphisms in genes affecting warfarin metabolism (cytochrome-P450 2C9, CYP2C9) and response (vitamin-K epoxide reductase complex 1, VKORC1) have an important influence on warfarin therapy, particularly during initiation. However, there is a lack of consensus regarding the optimal pharmacogenetics-based initiation strategy. We conducted a prospective cohort study in which patients requiring warfarin therapy for atrial-fibrillation (AF) or venous thromboembolism (VTE) were initiated using a novel pharmacogenetics-initiation protocol (WRAPID), incorporating loading and maintenance doses based on genetics, clinical variables and response (n=167, followed for 90 days), to assess the influence of genetic variations on anticoagulation responses. Application of the WRAPID algorithm resulted in negligible influence of genetic variation in VKORC1 or CYP2C9 on time to first therapeutic INR (2 -3; P=0.52, P=0.28) and risk of overanticoagulation (INR≥4; P=0.64, P=0.96). Following adjustment of covariates, time to stable anticoagulation was not influenced by VKORC1 or CYP2C9 genotype. Importantly, time spent within or above range did not differ among VKORC1 and CYP2C9 genotype groups. Moreover, the overall time-course of anticoagulation response among the genotype groups was similar and predictable. We demonstrate the clinical utility of genetics-guided warfarin initiation with the WRAPID protocol for providing safe and optimal anticoagulation therapy for AF and VTE patients.
Introduction
The vitamin K antagonist warfarin is an oral anticoagulant commonly prescribed in North America to treat venous thromboembolism (VTE) and decrease the risk of stroke in atrial fibrillation (AF).
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Warfarin therapy is challenging due to marked and often unpredictable interindividual dosing variation to reach and maintain adequate anticoagulation. For most indications, optimal warfarin therapy is achieved by maintaining the international normalized ratio (INR) within a narrow therapeutic range of 2.0 to 3.0. An insufficient warfarin dose leads to a lack of antithrombotic effect while overanticoagulation is associated with elevated bleeding risk.
Since the FDA revised the label for warfarin noting the importance of VKORC1 and CYP2C9 polymorphisms, 13 a number of groups have proposed genotype-guided maintenance dose algorithms that incorporate genetics as well as demographic parameters, such as age, weight, and body surface area (BSA). 14, 15 However, there is a paucity of information with respect to dosing during warfarin initiation, arguably the most clinically challenging therapeutic phase where the risk of haemorrhage and recurrent thromboembolism is greatest. 16, 17 Standardized loading dose nomograms developed to date have not considered genetics and other patient-specific characteristics and have not been applied to indications other than VTE, such as AF. [18] [19] [20] We and others have recently shown that VKORC1 and CYP2C9 genetic variations modulate early and stable response to warfarin during initiation when dosing by traditional means. [21] [22] [23] [24] Thus, in this study, a novel and practical VKORC1 and CYP2C9-based loading and maintenance dose algorithm (WRAPID, Warfarin Regimen using A Pharmacogeneticsguided Initiation Dosing-protocol) was developed and evaluated in AF and VTE patients with the aim to provide a safe, rapid and uniform anticoagulation response.
Materials and Methods

Study sample and eligibility
This was a prospective cohort study of outpatients conducted at the London Health Sciences Centre (LHSC) and the Ottawa Hospital (TOH). The study was approved by Research Ethics Boards at the University of Western Ontario and TOH. Patients requiring initiation of warfarin therapy were screened for eligibility. The requirement for warfarin therapy was determined based on current American
College of Chest Physicians guidelines. 1 Patients who met the eligibility criteria were enrolled upon
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From provision of written informed consent in accordance with the Declaration of Helsinki. Table 1 summarizes patient characteristics.
Study eligibility was determined by the following inclusion criteria: at least 18 years of age, and indication for new warfarin therapy for at least 3 months with a target INR range of 2.0 to 3.0.
Exclusion criteria were: diagnosis of cancer other than non-melanoma skin cancer, alcohol or drug abuse, baseline INR>1.4, known warfarin allergy/intolerance, terminal disease, prior use of warfarin therapy or vitamin K within 2 weeks prior to study enrolment, as well as known/suspected pregnancy.
Clinical data collection and follow-up
Demographic information was obtained at the time of enrolment. Therapy-related information was collected by patient interview and review of medical records. A baseline venous blood sample was obtained for DNA extraction and assessment of INR. Subsequent INR measurements, dose adjustments, adverse events, and therapy-related interventions were recorded at both study sites. The study period was September 2008 to August 2010.
Genotyping
Genomic DNA was isolated with Gentra Puregene or DNA Blood Midi extraction kit according to manufacturer's protocol (Qiagen, Alameda, CA). Genotype analysis included CYP2C9*2, CYP2C9*3, VKORC1 -1639G>A and CYP4F2 c.1297G>A. At LHSC, genotypes were determined by allelic discrimination using TaqMan Drug Metabolism Genotyping assays with the 7500 RT-PCR System (assay IDs: C__25625805_10, C__27104892_10, C__1329189_10, C__16179493_40; Applied Biosystems, Foster City, CA). At OHRI, genotypes were determined using the Luminex 200 system (Luminex, Austin, TX). Briefly, forward and reverse primers for SNPs of interest were designed to amplify regions surrounding each SNP using standard multiplex PCR protocols. The PCR products For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From were then hybridized with appropriate xMAP Carboxylated Microspheres at 52°C, followed by analysis with the Luminex 200. Genotyping was generally performed within 24 hours of receiving the baseline blood sample and utilized prospectively to determine individualized initiation doses prior to warfarin commencement for all study subjects.
Mathematical foundation for a novel pharmacogenetics-based initiation protocol
Using historical datasets compiled from Vanderbilt University (n=297) 24 and TOH (n=63) 25 , we developed a pharmacogenetics-based initiation protocol aimed at providing uniform anticoagulation response among all patients. The dosing regimen comprises of both a loading and maintenance dose algorithm. Development of the loading and maintenance dose algorithms required the integration of pharmacokinetic (PK) and pharmacodynamic (PD) factors to predict the time-course of warfarin plasma levels and response.
In this mechanistic model, plasma PK of warfarin was described using a simple one-compartment model for warfarin distribution of a set volume (V). The time-course of estimated plasma S-warfarin concentration (C plasma ) arose from the interplay between drug absorption in the gut (k a ) and drug elimination via CYP2C9 metabolism (k e ). Values for kinetic parameters for S-warfarin were obtained from the literature. [26] [27] [28] [29] Warfarin metabolism capacity (k e ) is mainly dependent on CYP2C9 genotype; thus, the values for k e were adjusted based on reported clearance reductions in heterozygous and homozygous variant allele carriers of either CYP2C9*2 or *3. 29 The pooling of genotypes into three subgroups was owing to the lack of confidence in the accuracy of limited available clearance rates reported in literature for CYP2C9*2/*2, *2/*3, and *3/*3 genotype groups as a result of low allelic frequencies.
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For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Warfarin PD was described by an indirect response model which incorporates the known delay and magnitude of anticoagulation effects after achieving the required plasma concentration. 30 In this model, the degree of suppression of vitamin K-dependent clotting factor production relates to the effectiveness of warfarin concentrations to inhibit VKOR. Here, the rate of change in INR is modeled using zeroorder input (K) and first-order output (k o ) variables. Plasma warfarin levels dictate the inhibition of output response according to classical competitive enzyme inhibition kinetics described by parameters I max (enzyme content and intrinsic activity) and IC 50 (drug affinity). 31 I max values corresponding to VKORC1 genotypes were determined upon simulating maintenance drug administration to stable therapeutic coagulation. Depiction and parameters of the PK-PD model are shown in Figure S1 .
It should be noted that the PK-PD model and corresponding parameter values presented here is preliminary and served only to guide the establishment of a practical WRAPID dosing protocol for various VKORC1 and CYP2C9 genotype combinations. A finalized version of the PK-PD model with data-derived parameter values based on formal modeling of R/S-warfarin concentrations and INR measurements obtained in this patient cohort, along with identification of key non-genetic and genetic determinants of warfarin kinetics and responses will be published elsewhere.
Loading doses
Practical (5 mg, 7.5 mg, 10 mg) daily loading doses were prescribed for 2 days and were dependent on VKORC1 and CYP2C9 genotypes (Table 2) . These doses were aimed to obtain sufficient warfarin plasma concentrations to reach and maintain optimal anticoagulation response (INR 2.0 -3.0) with similar rapid initial time-course for all genotype groups ( Figure S2 ).
Maintenance doses
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From To obtain the maintenance dose, key patient clinical parameters that are known to influence warfarin dose requirement along with genetics were combined in a generalized linear regression model (GLM ,   Table 3 ). Briefly, warfarin dose was the dependent variable, VKORC1 and CYP2C9 genetics-based dose was a constant variable (Table 4 ) and coefficients of independent variables were varied according to least-squares linear regression method.
Following the two-day loading dose, patients were prescribed the calculated maintenance dose to begin on day 3. On 3 occasions within the first 9 days of therapy (initiation), INR measurements were obtained (typically days 3, 5/6 and 7/8/9) since this frequency of INR measurements has been shown to be practical and efficacious for anticoagulation management. 19 When the INR response at each measurement did not conform to the predicted trajectory based on the mathematical model, the daily maintenance dose was further adjusted according to a treatment day-specific dose adjustment nomogram (Table 5 ). Adjusted doses were rounded to either the nearest whole number or 0.5.
To make dosing practical, we devised an automated dose calculator for the initiation phase ( Figure 
Refinement of loading and maintenance dose algorithm
It was our objective to refine the loading and maintenance dose algorithm after an initial cohort of patients (n=87) for application in a final cohort. Following the initial cohort, we observed a disproportionate number of out-of-range INR response in those patients with high loading dose to
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From weight ratio. Thus, we modified the loading dose algorithm to consider weight after the first cohort. For patients less than 60 Kg with a 10 mg load according to the original loading algorithm, we decreased the dose to 7.5 mg. For patients less than 45 Kg, all loading doses were decreased by 2.5 mg (7.5 to 5 mg, and 5 mg to 2.5 mg).
Planned optimization of the maintenance dose regression was performed by slightly modifying the contribution of clinical parameters to dose while the impact of VKORC1 and CYP2C9 remained unchanged. In univariate analysis, we observed a significant relationship between CYP4F2 c.1297G>A genotype and dose, where A/A carriers required 1 mg higher warfarin dose than the wild-type group (P<0.05). Thus, we included CYP4F2 genotype in the final regression model to determine maintenance doses of the final cohort.
Sample size
The WRAPID study was powered to assess the effect of VKORC1 -1639G>A genotype on anticoagulation response, following pharmacogenetics-guided initiation. A study size of 150 patients was estimated to have 80% power to detect a response hazard of 2 at a two-sided significance level of 0.05, allowing for a dropout rate of 10%. Hazard ratio (HR) of 2 was chosen based on previously published VKORC1-carrier status hazard risk for primary outcomes. 24 Power analysis was performed using SAS v. 9.2 (SAS, Cary, NC).
Primary and secondary outcomes
The primary outcomes of this study were time to first therapeutic INR, time to first overanticoagulation (INR≥4). We choose these primary outcomes as they are critical markers of anticoagulation pace and quality of control. Therapeutic INR was defined as 2.0 -3.0 for all patients. The outcomes were selected to assess the influence of VKORC1 genotype on anticoagulation response.
Although this study was not powered to evaluate the individual effects of CYP2C9*2 and *3 genotypes on response, analysis was conducted comparing wild-type and any CYP2C9 variant-carrier status.
Statistical analysis
Patients were divided into 3 groups for VKORC1 and 2 groups for CYP2C9: VKORC1 wild-type, heterozygous, and homozygous carriers of -1639G>A; CYP2C9 wild-type (*1/*1), and variant group included one or two variant allele carriers (*1/*2, *1/*3; *2/*2, *3/*3 or *2/*3). Hardy-Weinberg equilibrium was assessed for each genotype using the chi-square goodness-of-fit test.
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The influence of VKORC1 and CYP2C9 genotype on the primary outcomes was evaluated using survival analysis techniques. Kaplan-Meier plots were used to depict proportion of subjects without events over time. Comparison between survival curves was conducted by the log-rank test. Unadjusted HR and its 95% confidence interval (CI) between genotype groups were computed. The Cox proportional hazard model was adopted to adjust for potential confounding effects of age, gender, weight, warfarin dose, amiodarone use, indication, patient cohort, VKORC1, CYP2C9 and CYP4F2
genotype to obtain adjusted HRs and its 95% CI. For comparison of differences in outcomes between patients with varying VKORC1 status, G/G genotype was considered as the reference group since it is the most warfarin-resistant group. Statistical analysis of Schoenfeld residuals and visual inspection of log-minus-log plots revealed no significant variation from the proportional hazards assumption.
Percent TIR and time spent above therapeutic range were compared among VKORC1 and CYP2C9
genotype groups with the use of Kruskal-Wallis followed by Tukey-Kramer's post-test or MannWhitney test, as appropriate.
It should be noted that all enrolled patients (initial and second cohort) were included for outcome analysis in order to obtain at least 80% power to detect the association of VKORC1 genotype and response. This was acceptable as there were no statistical differences between the two cohorts with respect to primary outcomes of time to first therapeutic INR and time to first INR≥4. In addition, potential variations between cohorts due to dosing regimen modifications were accounted for as a confounding variable in the Cox regression analysis of primary survival data and should not interfere with assessment of genetic variation effects on rate of INR anticoagulation responses. Since no significant differences were observed between initial and second cohort for secondary outcomes, both patient groups were combined for secondary analysis.
To assess and compare the predictability of our dosing model, we determined the association between maintenance dose and model-derived dose. The proportion of variance explained was calculated as the R 2 statistic. In addition, we determined the mean absolute error (MAE) of each model for the same purpose.
A two-tailed P-value of less than 0.05 was considered significant for all analyses. Statistical analysis was performed with the use of GraphPad Prism v.5.0 (GraphPad, La Jolla, CA) or SPSS v. 17.0 (SPSS, Chicago, IL).
Results
Population characteristics
Of the 196 patients enrolled, 29 were excluded from analysis for the following reasons: 3 due to entry error, 4 self-administered the wrong dose, 1 failure to comply with INR measurements, 14 drop-outs, 6
due to incomplete follow-up and 1 death (cause not attributed to study participation). Of those included for outcome analysis, 61 and 96 patients were enrolled at LHSC and TOH, respectively.
The allelic frequencies for VKORC1 -1639G>A and CYP4F2 c.1297G>A were 38.0% and 31.7%, respectively. The CYP2C9*2 and *3 allelic frequencies were 11.1% and 4.8%, respectively. There were no deviations from the Hardy-Weinberg equilibrium.
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Time to first therapeutic INR (2.0-3.0), over-anticoagulation (INR≥4), and stable anticoagulation
The primary outcomes were compared in terms of VKORC1 and CYP2C9 genotypes. VKORC1
genotype had no significant effect on time required to reach the first INR within therapeutic range (P=0.52) or time required to obtain an INR≥4, according to log-rank test (P=0.64) ( Figure 1A, 1C) .
Similarly, there was no significant difference between CYP2C9 wild-type and variant genotype for either of these outcomes (P=0.28 for first INR, P=0.96 for first INR≥4; Figure 1B , 1D). Concordant with these findings, HR estimates for VKORC1 and CYP2C9 genotype groups were not significantly different from unity before or after adjusting for covariates using Cox regression analysis (Table 6 ).
Since outcomes during the first 30 days would be most sensitive to the initiation protocol, we compared the time to first INR≥4 during the first month of therapy among genotype groups. VKORC1 and CYP2C9 polymorphisms were without influence on this outcome (data not shown). Importantly, these outcomes were not associated with genotype when considering first and second cohort patients independently (data not shown).
Time to stable anticoagulation
The time to first stable anticoagulation was significantly different between VKORC1 (P<0.05) genotype groups, while there were no differences between CYP2C9 groups (P=0.37, Figure 2 ). However, when adjusted for confounding covariates, neither VKORC1 nor CYP2C9 showed significant influence on time to stability (Table 6 ).
Time spent within therapeutic range and above therapeutic range (INR>3)
To separate the initiation and stabilization phases of therapy, we considered pre-stabilization as day 1 to 30 and the stabilization phase as day 31 to the end of study period. We chose 30 days because the median time to stability was 29 days. There was no significant influence of VKORC1 or CYP2C9 1 4
genotype on time spent in therapeutic range or above range during pre-stabilization or stabilization phase (Table S1 ). We note that the present study was not powered to detect secondary outcomes.
INR response time course during first three weeks of therapy
Using the PK-PD model, the response profiles for various genotype groups were predicted to be similar during the attainment of therapeutic INR. It is important to note that our algorithm was developed to reach first therapeutic response in a steady and safe manner, with a goal of reaching optimal anticoagulation by end of initiation. Figure 3A 
Secondary outcomes
Secondary efficacy and safety outcomes of anticoagulation are summarized in Table 7 . By day 6 of therapy, 40.1% of patients enrolled in our study had an INR within therapeutic range while 57.5% had an INR within therapeutic range by day 9. The proportion of patients reaching extended INR range of 1.8-3.2 by day 6 and 9 was 60.5% and 78.4%, respectively. Although approximately 20% of patients reached an INR≥4 during the entire study duration, percent time spent with INR≥4 was only 1.2%.
Moreover, only 3.6% of patients experienced excessive over-anticoagulation of an INR≥5 during the entire study period. The average maintenance dose was 5.54 mg/day and followed the known genedose relationship (Table S2) .
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Dosing algorithm assessment
The association between observed maintenance dose, algorithm predicted and day 7/8/9 dose was determined. The proportion of variance explained by the final maintenance regression was 42% ( Figure   4A ), while the variance explained following INR-guided dose adjustments was 70% ( Figure 4B ). In addition, there was less bias between day 7/8/9 dose and maintenance dose than that of the algorithm predicted. The MAE (standard error, SEM) of the final model was 10.4 (0.1) mg/week while the INRadjusted dose was 8.5 (0.9) mg/week, comparable to that of other pharmacogenetics-based nomograms.
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Discussion
The clinical benefit of warfarin to decrease stroke risk among AF patients and treat VTE is well established. However, the unpredictable anticoagulation response for a significant proportion of patients poses a substantial clinical challenge to optimal warfarin therapy. Several studies have examined various initiation strategies for treatment of VTE and AF. genotype is sufficient. This is consistent with the fact that CYP4F2 genotype only accounts for a small portion of the observed maintenance dose variability (0-4%). 12, 41 However, a caveat here is that the present study was not powered to detect an association between response and CYP4F2 genotype. Thus, the definitive role of CYP4F2 genotype in individualized warfarin therapy requires further assessment in a powered study of sufficient sample size.
With respect to risk for excessive anticoagulation (INR≥4), several groups have reported that variant carriers of VKORC1 and CYP2C9 are subject to significantly increased risk of over-anticoagulation.
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Following initiation with pharmacogenetics-based dosing algorithm, neither VKORC1 nor CYP2C9 variant groups were associated with elevated risk of supra-therapeutic INR during the first month of therapy or the entire study period. Our findings contrast with those of a study conducted by Voora et al.
where patients were prospectively dosed only according to CYP2C9 genotype. 42 In that study, carriers of a variant CYP2C9 allele still exhibited an increased risk for excessive anticoagulation. This may be explained by dosing algorithm and adjustment differences during initiation compared to the present study. It cannot be entirely ruled out that lack of association observed in the present study may be due to insufficient sample size. However, calculations showed that we had ample power (> 80%) to detect the association of causal VKORC1 -1639G>A SNP, with an allele frequency of 35%, to anticoagulation response for a HR of 2. Since we observed no evidence of association between VKORC1 genotype and anticoagulation responses, it would be reasonable to conclude that the WRAPID algorithm eliminated VKORC1-driven response variation. Although we did not observe a significant association between CYP2C9*2 or *3 genotype and response, this may be due to lack of power. Considering the small proportion of heterozygous and homozygous carriers of CY2C9*2 and *3 allele, the sample size powered to detect such individual associations would be very large (~1000). Thus, we assessed the association of pooled CYP2C9 variant status (at least one of *2 or *3 allele), a frequency of 30% in our population, on anticoagulation response. In this case, calculation showed that sufficient power was achieved (> 80%) to detect the association of CYP2C9 variant status to anticoagulation responses for a HR of 2. Such pooling of CYP2C9*2 and *3 variants has certainly been previously used by other studies for similar reasons. 8, 43, 44 Particularly, these studies demonstrated that in patients initiated with
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From standard-dosing protocols, pooled CYP2C9 variants spent more time above therapeutic INR, associated with elevated risk of over-anticoagulation, and lowered dose requirement overall.
To our knowledge, the WRAPID nomogram is the first warfarin initiation algorithm incorporating both VKORC1 and CYP2C9 genotype-determined loading doses, which differs from the typical doubling of maintenance dose. Thus far, there are two prospective randomized clinical trials (RCTs) where pharmacogenetics-based warfarin initiation with loading doses was compared with standard warfarin loading dose initiation, while other studies do not incorporate loading doses. In the first trial, control patients were loaded with 5 mg while study patients were loaded according to CYP2C9 genotype. 45 In the second trial, control patients were initiated with 10 mg while study patients were initiated with double the maintenance dose determined with VKORC1 and CYP2C9. 46 Evidently, there is a lack of consensus with respect to warfarin initiation and especially concerning loading dose selection from genetic information. The aforementioned trials, albeit small, indicate that pharmacogenetics-guided dosing improved warfarin response, in terms of more time spent within therapeutic range, decreased bleeding events and faster attainment of therapeutic INR, supporting the use of loading doses for initiation. Additionally, some studies recommend that loading dose should be age adjusted due to concern of warfarin sensitivity. 34 However, we did not observe a disproportional number of elderly patients with excessive anticoagulation under our loading dose regimen, where some elderly patients were indeed loaded with 10 mg as per genotype. Thus, our data do not support age-modified loading doses. We did, however, observe an effect of decreased weight on response sensitivity during initiation.
Limitations of this study include the inability to determine the influence of pharmacogenetics-guided dosing algorithm on rare bleeding complications, due to insufficient sample size. However, we can comment on the general safety of our dosing regimen. The number of INRs over 5 has been previously 1 9
used as a measure of safety of a dosing protocol. 19 In this study, only 3.6% of patients experienced such excessive anticoagulation, which is lower than that observed with other initiation protocols (5.6 -8.6%). 19, 36 A number of RCTs involving larger sample sizes are currently underway to evaluate safety and efficacy of pharmacogenetics-based dosing compared to standard-dosing (www.clinicaltrials.gov).
Interestingly, a proposal has been made for a multicentre trial in Europe that will test pharmacogenetics-guided initiation with the use of genotype-based loading doses to examine the clinical utility of such dosing methods. The present study supports the use of genotype-guided loading dose during warfarin initiation. Another limitation is that since our study lacked a control group (nongenetics based warfarin initiation), the results may be partly attributed to management of warfarin therapy by anticoagulation clinics. However, we note that our study was not designed as an RCT, rather with the goal of demonstrating the minimization of genotype-dependent differences in early anticoagulation response, as this has not been conclusively demonstrated in the warfarinpharmacogenetics field. Furthermore, several studies published thus far described the contribution of genetic variations to initial warfarin response variability in patients initiated with respective anticoagulation clinic regimens, likely with similar INR-response monitoring schedules as WRAPID. 22, 23, 43 Thus, we believe that pharmacogenetics-based initiation, particularly with the use of loading doses, should result in safe and similar rise to optimal anticoagulation responses amongst VKORC1 and CYP2C9 genotype groups. Supportive of the role of genotype-guided initiation for warfarin therapy, a recent study suggests that genotyping for patients initiating therapy significantly reduced hospitalization rate for bleeding or thromboembolic event compared to a control group.
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Furthermore, five small RCTs (range from 38-200 patients) completed thus far largely suggest that pharmacogenetics-guided dosing improved warfarin response, in terms of more time spent within therapeutic range and decreased bleeding events as compared to standard-dosing 45, 46, 48, 49 , with the exception of one study in orthopaedic patients 50 . In that RCT, patients were followed for only 2-4 0 weeks and daily INR monitoring in addition to similar dose adjustment protocol between the two arms may have rendered the effect of genotype-guided dosing non-significant. Indeed, larger RCTs which incorporate models such as WRAPID are required to compare adverse event rates between standard and pharmacogenetics-guided dosing of warfarin-based anticoagulation.
To our knowledge, this is the first prospective study to demonstrate the utility of a genotype-guided warfarin initiation algorithm for the minimization of widely recognized VKORC1 and CYP2C9
genotype-associated differences in anticoagulation response for both AF and VTE patients. The pharmacogenetics-based algorithm proposed here is feasible and effective for outpatient management of individuals requiring warfarin-based anticoagulation.
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